Jasper Therapeutics reports favorable safety profile and deep clinical responses for briquilimab in CSU patients, advancing to Phase 2b trials in late 2025.

We give you the tools to engage with your donors and raise more for your charity

The appointed leaders of the U.S. Department of Health and Human Services must understand the science and support the importance of vaccines and herd immunity for ensuring the health and well-being of...